Background/objectives: As a primary source of mortality and disability, bacterial infections continue to develop a severe threat to humanity. Nuclear medicine imaging (NMI) is known for its promising potential to diagnose deep-seated bacterial infections. This work aims to develop a new technetium-99m (Tc) labeled tigecycline radiopharmaceutical as an infection imaging agent.
View Article and Find Full Text PDF